Evaluation of Genetic Polymorphisms in Glutathione S-Transferase Theta1, Glutathione S-Transferase Mu1, and Glutathione S-Transferase Mu3 in Oral Leukoplakia and Oral Squamous Cell Carcinoma with Deleterious Habits using Polymerase Chain Reaction

Abstract

Context: Oral squamous cell carcinoma (OSCC) is the sixth most common cancer in the world. As per previous studies, most patients who develop oral cancer are elderly males who are heavy users of tobacco and alcohol; however, the incidence is increasing in younger individuals and in those who neither smoke nor drink. Many of the genes that code for the detoxification enzymes are polymorphic with abnormal activity profiles. Aims and Objectives: The aim of this study was to evaluate the risk of development of oral leukoplakia (OLP) and OSCC in glutathione S-transferase polymorphisms genes in the east coast of Andhra Pradesh population with tobacco consumption habit and habit-free controls using polymerase chain reaction (PCR-restriction fragment length polymorphism). Materials and Methods: This study included 15 patients each with histologically proven epithelial dysplasia and OSCC and compared with age- and gender-related controls with no tobacco habits in any form. A volume of 2 ml of blood sample was collected into presterilized vials containing ethylenediaminetetraacetic acid from each individual under aseptic conditions. DNA extraction was whole from blood, and PCR was performed. Statistical analysis was performed using Chi-square test and odds ratio (OR) and 95% confidence intervals (CIs). Results: The results are suggestive that glutathione S-transferase mu1 (GSTM1) null was associated with increased risk of OLP (OR = 5.5, 95% CI = 1.14–26.41, P = 0.021) and OSCC (OR = 11, 95% CI = 1.99–60.5, P = 0.021). Glutathione S-transferase theta1 (GSTT1) null genotype was associated with increased risk of OLP (OR = 2.154, 95% CI = 0.74–6.762, P > 0.99) and OSCC (OR = 2.154, 95% CI = 0.74–6.762, P > 0.99). The glutathione S-transferase mu3 (GSTM3) AB + BB genotypes appear to be risk factors for OSCC (OR = 1.31, 95% CI = 0.31–5.58, P = 0.7) although statistically insignificant. Conclusion: Hence to conclude, because of small sample size in the present study, statistically insignificant results were found and this study failed to observe the relationship between GSTM3 and GSTT1 polymorphism and risk of developing OSCC and positive relationship was observed with GSTM1 polymorphism and risk of developing OSCC.

Keywords: Glutathione S-transferases, polymerase chain reaction, polymorphisms

Introduction

Oral potentially malignant disorders are OLP, erythroplakia, and oral submucous fibrosis of which OLP is the most common.[1] The incidence rates of OLP are increasing for many years as the commercially available tobacco products are freely available in many Asiatic countries including India.[2] The prevalence of tobacco use among men is high (>50%) from almost all parts of India, the prevalence is more in rural than in urban areas.[3] Incidence rates of OLP per 1000 individuals per year varied from 1.1 to 2.4 among men and 0.2–1.3 among women.[4] Malignant transformation rate of OLP worldwide is 3.6% and in India varies from 0.13% to 10%.[5] Globally, Oral cancer ranks sixth in the cancer burden.[6] In India, incidence rates of oral squamous cell carcinoma (OSCC) are 7–17 per 100,000 persons per year. Around 75,000–80,000 new cases develop in India every year.[7]

As an early sign of damage to oral mucosa by the carcinogens in tobacco smokers and chewers, visible alterations occur and appear usually as white patches with or without red patches. These changes are...
usually precancerous.\textsuperscript{[1]} OLP, the common premalignant lesion among the smokers. In 2005, the World Health Organization defined it as “a white plaque of questionable risk having excluded (other) known diseases or disorders that carry no increased risk for cancer.”\textsuperscript{[8]} This lesion is easily accessible to diagnosis and can be considered as indicators of oral cancer risk. The consequence of malignant transformation of OLP is OSCC. OSCC is defined as a malignant epithelial neoplasm exhibiting squamous differentiation as characterized by the formation of keratin and/or the presence of intercellular bridges.\textsuperscript{[7]}

This cancer is a global burden to humanity, and lifestyle-related addictive habits such as tobacco smoking, chewing, and alcohol consumption are the main culprits. Chemical carcinogens from smoking and chewing of tobacco and betel-quid act synergistically in oral carcinogenesis and that persons with mixed habits form a substantially high-risk population.\textsuperscript{[9]}

Polycyclic aromatic hydrocarbons (PAHs), aldehydes, ethylene oxide, aromatic amines, and nitrosamines are thought to be carcinogenic components present in tobacco smoke. In general, PAHs are carcinogens that act locally and other carcinogenic agents act systemically. Some PAHs, such as benzopyrene (BP), have powerful carcinogenic activity.\textsuperscript{[10]} However, chewing tobacco with betel quid increases concentrations of carcinogenic tobacco-specific nitrosamines and reactive oxygen species in mouth.\textsuperscript{[11]}

Chemicals that initiate carcinogenesis can act directly or indirectly. Direct carcinogens do not require metabolic conversion to become carcinogenic and are weak carcinogenic agents such as alkylating and acylating. Indirect carcinogens require metabolic conversion to become active carcinogen such as PAH, BP, and ethylene oxides.\textsuperscript{[12]}

Cytochrome P450s are mostly the Phase I enzymes involved in the activation pathway in the liver.\textsuperscript{[13]} These enzymes catalyze the introduction of a functional group such as an epoxide into PAH and BP, which offers electrophilic intermediates that can damage DNA.\textsuperscript{[7,13]}

Elimination of these reactive electrophilic intermediate metabolites requires action by Phase II enzymes such as N-acetyltransferases,\textsuperscript{[13]} glutathione S-transferases (GSTs)\textsuperscript{[4,12]} that converts them into water-soluble excretable compounds. Human GSTs are divided into three main families: Cytosolic or soluble, mitochondrial, and membrane-bound microsomal. Sixteen members of GST superfamily have been identified in humans so far.\textsuperscript{[14]}

Of which four members of the GST genes - glutathione S-transferase mu3 (GSTM3), glutathione S-transferase theta1 (GSTT1), glutathione S-transferase mu1 (GSTM1), and glutathione S-transferase pi1 (GSTP1) display polymorphisms that have been associated with increased risk for cancers.\textsuperscript{[4,15,16] Among them, GSTM and GSTT
GSTM1 gene separately in a conventional PCR (Corbett Research Australia). The sequences of primers used for PCR amplification are mentioned in Table 1.

DNA samples were mixed with the appropriate amount of gel loading buffer. The electrodes were connected to a power pack; running of the gel was done until the marker dyes have migrated to the desired distance. The gels were stained with ethidium bromide, and the dried gels were exposed to phosphorimager screen.

**Statistical analysis**

The comparison of GSTT1, GSTM1 null genotype, and GSTM3 polymorphisms among controls without habits, OLP and OSCC, was done using Statistical Package for Social Sciences Software 17 version (SPSS, Chicago, IL, USA). Statistical comparison of GSTT1, GSTM1 null genotype, and GSTM3 polymorphisms with tobacco habits in controls with habits and OLP, OSCC individuals was done and was analyzed using Chi-square test and Fischer’s exact t-test. Odds ratio (OR) and 95% confidence intervals (CIs) were calculated for GSTT1, GSTM1 null genotypes, and GSTM3 polymorphisms in controls with habits and OLP, OSCC individuals.

**Results**

Distribution of GSTT1 genotype among controls, OLP and OSCC using Chi-square test, relative risk of GSTT1, OLP, OSCC, and controls with OR and 95% CI [Table 2].

The PCR analysis showed that the GSTT1 null genotype was greater in OLP and OSCC (13.3%) in comparison to the controls (6.7%) indicating the absence of GSTT1 increases risk of developing OLP and OSCC (P value nonsignificant >0.99).

Distribution of GSTM1 genotype among controls, OLP, and OSCC using Chi-square test, relative risk of GSTM1, OLP, OSCC, and controls with OR and 95% CI [Table 3].

The PCR analysis showed that the GSTM1 null genotype was greater in OLP (66.7%) and OSCC (80%) in comparison to the controls (26.7%) indicating null GSTM1 increases the risk of developing OLP and OSCC (P value: Statistically significant).

Distribution of GSTM3 genotype among controls, OLP, and OSCC using Chi-square test, relative risk of GSTM3 AB + BB, OLP, OSCC, and controls with OR, 95% CI [Table 4].

The PCR analysis showed that the GSTM3 AB + BB polymorphisms increase the risk of developing OLP and OSCC (P value nonsignificant).

**Discussion**

Some heavy smokers and chewers do not develop precancerous states and cancer even after prolonged periods of usage while such lesions are seen in early smokers and even in nonsmokers. Differences in carcinogen metabolism and DNA repair due to polymorphisms are suggested for this variance in susceptibility. Hence, individual’s susceptibility to OLP and cancer is modulated by both environmental and genetic factors which are confirmed by molecular epidemiologic studies.

In this study, we examined the association between polymorphisms in GSTs genes and the associated risk of OLP and OSCC among the east Coast of Andhra Pradesh tobacco users. The null genotype percentage varies in ethnic groups and also in geographical locations. In various previously conducted studies, the null genotype was reported to be deleted in 12%–27% of Brazilian population,[19,20] 48% of Taiwan population,[21] 18% of the US population.[13,22] Similarly in India, it was observed to be 16%–25% in Mumbai,[23–25] 8% in Thrivananthapuram.[26] In the present study, GSTT1 null genotype was greater in OLP and OSCC (13.3%) in comparison to the controls (6.7%). Although the study is statistically insignificant, it suggests a positive association between GSTT1 null genotype and OLP and OSCC. One study conducted in 1999 by Cheng et al.[22] in Houston, USA, found that 32.7% of cases and 17.5% of controls were null for GSTT1. These results are in relation to the present study and are in contrast to studies of Olshan et al.[19] Buch et al.[24] on Mumbai population who found no difference of null genotype between cases and controls and interestingly Anantharaman et al.[25] even found that GSTT1 null genotype conferred reduced risk to OSCC. The OR associated with the GSTT1 null genotype was increased, (OR = 2.154; 95% CI = 0.74–26.672) although not significantly, it suggests a positive association between GSTT1 null genotype and OLP and OSCC. One study conducted in 1999 by Cheng et al.[22] (OR = 2.475; 95% CI = 0.2821–21.712), Cheng et al.[22]

**Table 1: Primers of β-actin, Glutathione S-transferase theta1, Glutathione S-transferase Mu3, β-globin, Glutathione S-transferase Mu1**

| Gene          | Forward primer (5'-3') | Reverse primer (5'-3') | Base pair |
|---------------|------------------------|------------------------|-----------|
| β-actin       | 5'-AGG CAC CAG GGC GTG AT-3' | 5'-GCC CAC ATA GGA ATC TGG AC-3' | 800       |
| GSTT1         | 5'-TTC CTT ACT GGT CCT CAC ATC TC-3' | 5'-TCA CCG GAT CAT GGC CAG CA-3' | 480       |
| GSTM3         | 5'-CCT CAG TAC TTG GAA GAG CT-3' | 5'-CAG ATG AAA GCC TTC AGG TT-3' | 280       |
| β-globin      | 5'-CAA CTT CAT CCA CGT TCA CC-3' | 5'-GAA GAG CCA AGG ACA GGT AC-3' | 268       |
| GSTM1         | 5'-GAA CTC CCTGAA AAG CTA AAG C-3' | 5'-GTT GGGCTCA AAA TAT ACG GTG G-3 | 215       |

GSTM1: Glutathione S-transferase theta1; GSTM3: Glutathione S-transferase Mu3; GSTM1: Glutathione S-transferase Mu1
Table 2: Distribution of glutathione S-transferase theta1 genotype among controls, oral leukoplakia and oral squamous cell carcinoma using Chi-square test, relative risk of glutathione S-transferase theta1, oral leukoplakia and oral squamous cell carcinoma, and controls with odds ratio and 95% confidence interval

| Group       | Controls, n (%) | OLP, n (%) | OSCC, n (%) |
|-------------|----------------|------------|-------------|
| GSTT1       |                |            |             |
| Null        | 1 (6.7)        | 2 (13.3)   | 2 (13.3)    |
| Wild        | 14 (93.3)      | 13 (86.7)  | 13 (86.7)   |
| P           | >0.99          | >0.99      | >0.99       |
| OR and 95% CI |           |            |             |
| OR          | 2.154          | 0.74-26.672| 0.55        |
| 95% CI      | 0.74-26.672    | 0.55       | 0.55        |
| P           | >0.99          | >0.99      | >0.99       |

OLP: Oral leukoplakia; OSCC: Oral squamous cell carcinoma; OR: Odds ratio; CI: Confidence interval; GSTT1: Glutathione S-transferase theta1

Table 3: Distribution of glutathione S-transferase Mu1 genotype among controls, oral leukoplakia and oral squamous cell carcinoma using Chi-square test, relative risk of glutathione S-transferase Mu1, oral leukoplakia, oral squamous cell carcinoma, and controls with odds ratio and 95% confidence interval

| Group       | Controls, n (%) | OLP, n (%) | OSCC, n (%) |
|-------------|----------------|------------|-------------|
| GSTM1       |                |            |             |
| Null        | 11 (26.7)      | 10 (66.7)  | 12 (80.0)   |
| Wild        | 4 (73.3)       | 5 (33.3)   | 3 (20.0)    |
| P           | 0.918          | 0.52       |             |
| OR and 95% CI |           |            |             |
| OR          | 1.99-60.5      | 0.003      | 0.021       |
| 95% CI      | 1.99-60.5      | 0.003      | 0.021       |
| P           | 0.38-10.51     | 0.409      |             |

OLP: Oral leukoplakia; OSCC: Oral squamous cell carcinoma; OR: Odds ratio; CI: Confidence interval; GSTT1: Glutathione S-transferase theta1; GSTM1: Glutathione S-transferase Mu1

Table 4: Distribution of glutathione S-transferase Mu3 genotype among controls, oral leukoplakia and oral squamous cell carcinoma using Chi-square test, relative risk of glutathione S-transferase Mu3 AB + BB, oral leukoplakia, oral squamous cell carcinoma and controls with odds ratio, 95% confidence interval

| Group       | Controls, n (%) | OLP, n (%) | OSCC, n (%) |
|-------------|----------------|------------|-------------|
| GSTM3       |                |            |             |
| AA          | 9 (60.0)       | 10 (66.7)  | 8 (53.3)    |
| AB + BB     | 6 (40)         | 5 (33.3)   | 7 (46.7)    |
| P(OR)       | 0.705 (0.17-3.33) | 1.31 (0.31-5.58) |
| GSTM3: Glutathione S-transferase Mu3; OLP: Oral leukoplakia; OSCC: Oral squamous cell carcinoma; OR: Odds ratio

In Houston (USA) (OR = 2.27; 95% CI = 1.43–3.60). The same risk was also found in the studies of Hung et al. showing an adjusted OR = 3.1; 95% CI = 0.9–10.9.

Studies conducted by Sikdar et al., Sreelekha et al. and Bathi et al. in West Bengal, Kerala, and Karnataka, respectively, also confirmed that GSTT1 null had an increased risk for OLP and OSCC which are in correlation to the present study.

In the present study, GSTM1 null genotype, there was increased risk between the normal and OSCC subjects. The OR of null genotype in OSCC is two times greater than OLP and in OSCC is 11 times greater than the odds of null genotype in normal subjects, whereas odds of null genotype in OLP is 5.5 times greater than the odds of null genotype in normal subjects. These are in correlation with Duarte et al. and Bathi et al. who found an association between the GSTM1 null genotype and an increased risk of development of OLP and OSCC.

In this study, we found a higher frequency of the GSTM3 AA genotype in OLP patients than in controls and a lower frequency of GSTM3 AB genotype in OLP patients than in controls. This was in correlation to the studies conducted by Sikdar et al. and Majumder et al. where higher frequency of the GSTM3 AA genotype was observed in cases than in controls. The OR associated with the GSTM3 AB + BB genotype was slightly increased, the relative risk observed in the study was in relation to the studies conducted by Majumder et al., Jain et al. and Jourenkova-Mironova et al. They found a 2-fold risk of laryngeal cancer associated with the GSTM3 (AB or BB) genotype in relation to the present study.

Conclusion

In spite of small sample size and certain other limitations, in this present study, we observed a modest association between polymorphisms of GSTT1, GSTM1, and GSTM3 genotypes. This study suggests that GSTT1, GSTM1 null genotype; GSTM3 AB + BB null genotypes apparently play a significant role in mediating susceptibility for developing OLP and OSCC.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

References

1. Garg KN, Raj V, Chandra S. Trends in frequency and duration of tobacco habit in relation to potentially malignant lesion: A 3 years retrospective study. J Oral Maxillofac Pathol 2013;17:201-6.
2. Chadda R, Sengupta S. Tobacco use by Indian adolescents. Tob Induc Dis 2002;1:111-9.
3. Reddy KS, Gupta PC. Economic history of tobacco production: From colonial origins to contemporary trends. In: Report on
Tobacco Control in India. Joint Report Supported by Ministry of Health and Family Welfare, Government of India, Centre of Disease Control and Prevention. USA: World Health Organization; 2004. p. 19-32.
4. Sikdar N, Paul RR, Roy B. Glutathione S-transferase M3 (A/A) genotype as a risk factor for oral cancer and leukoplakia among Indian tobacco smokers. Int J Cancer 2004;109:95-101.
5. Sridharan G. Epidemiology, control and prevention of tobacco induced oral mucosal lesions in India. Indian J Cancer 2014;51:80-5.
6. Wannakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009;45:309-16.
7. Shafer WG, Hine MK, Levy BM. Benign and malignant tumors of oral cavity. In: Rajendran R, Sivapathasundaram B, editors. Shafer’s Textbook of Oral Pathology, 6th ed. Livingstone: Elsevier Company; 2009. p. 80-6.
8. Brouns ER, Baart JA, Bloemena E, Karagozoglu H, van der Waal I. The relevance of uniform reporting in oral leukoplakia: Definition, certainty factor and staging based on experience with 275 patients. Med Oral Patol Oral Cir Bucal 2013;18:e19-26.
9. Patil PB, Bathi R, Chaudhari S. Prevalence of oral mucosal lesions in dental patients with tobacco smoking, chewing, and mixed habits: A cross-sectional study in South India. J Family Community Med 2013;20:130-5.
10. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 1995;24:450-3.
11. U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease. A Report of the Surgeon General. Atlanta, GA: U.S. Cancer; 2010.
12. Kumar V, Abbas AK, Astar JC. Neoplasia. Robbins Pathological Basis of Disease. 9th ed. Philadelphia: Elsevier, Saunders; 2013. p. 322-4.
13. Olshan AF, Weissler MC, Watson MA, Bell DA. GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2000;9:185-91.
14. Chatterjee S, Rudra T, Poddar S, Chakrabarti S, Sengupta B, Biswas D, et al. GST and CYP polymorphism related to tea drinking and oral pathology. Int J Hum Genet 2008;8:295-9.
15. Sherratt, PJ, Hayes JD. Glutathione S-transferases, in Enzyme Systems that Metabolise Drugs and Other Xenobiotics (ed C. Ioannides), John Wiley & Sons, Ltd; Chichester, UK: 2001. p. 320-52.
16. Jain M, Kumar S, Lal P, Tiwari A, Ghoshal UC, Mittal B. Role of GSTM3 polymorphism in the risk of developing esophageal cancer. Cancer Epidemiol Biomarkers Prev 2007;16:178-81.
17. Jourenkova-Mironova N, Voho A, Bouchardy C, Wikman H, Dayer P, Benhamou S, et al. Glutathione S-transferase GSTM3 and GSTP1 genotypes and larynx cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:185-8.
18. Inskip A, Elexperu-Camiruaga J, Buxton N, Dias PS, MacIntosh J, Campbell D, et al. Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: Evidence for linkage with GSTM1*A. Biochem J 1995;312(Pt 3):713-6.
19. Rossini A, Rapozo DC, Soares Lima SC, Guimarães DP, Ferreira MA, Teixeira R, et al. Polymorphisms of GSTP1 and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1, modify the risk for esophageal cancer in a Western population. Carcinogenesis 2007;28:2537-42.
20. Drummond SN, Gomez RS, Motta Noronha JC, Pordeus IA, Barbosa AA, De Marco L. Association between GSTT1 gene deletion and the susceptibility to oral squamous cell carcinoma in cigarette-smoking subjects. Oral Oncol 2005;41:515-9.
21. Hung HC, Chuang J, Chien YC, Chern HD, Chiang CP, Kuo YS, et al. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev 1997;6:901-9.
22. Cheng L, Sturgis EM, Eicher SA, Char D, Spitz MR, Wei Q. Glutathione-S-transferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. Int J Cancer 1999;84:220-4.
23. Nair UI, Nair J, Mathew B, Bartsch H. Glutathione S-transferase M1 and T1 null genotypes as risk factors for oral leukoplakia in ethnic Indian betel quid/tobacco chewers. Carcinogenesis 1999;20:743-8.
24. Buch SC, Notani PN, Bhisey RA. Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population. Carcinogenesis 2002;23:803-7.
25. Anantharaman D, Chaubal PM, Kannan S, Bhisey RA, Mahimkar MR. Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: Tobacco exposure as a risk modulator. Carcinogenesis 2007;28:1455-62.
26. Sreelekha TT, Ramadas K, Pandey M, Thomas G, Nalinakumari KR, Pillai MR. Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol 2001;37:593-8.
27. Bathi RJ, Rao R, Mutalik S. GST null genotype and antioxidants: Risk indicators for oral pre-cancer and cancer. Indian J Dent Res 2009;20:298-303.
28. Duarte EC, Silva MS, Gomez MV, Gomez RS. GSTT1 polymorphism and oral OLP. Anticancer Res 2006;26:427-30.
29. Majumder M, Sikdar N, Paul RR, Roy B. Increased risk of oral OLP and Cancer among mixed tobacco users carrying XRCCL1 variant haplotypes and cancer among smokers carrying two risk genotypes: One on each of two loci, GSTM3 and XRCCL1. Cancer Epidemiol Biomarkers Prev 2005;14:2106-12.